文献速递淋巴瘤

富马酸二甲酯联合体外光分离置换疗法协同诱导皮肤T细胞淋巴瘤特异性细胞死亡并实现长期缓解

Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma.
PubMed 文献 · Leukemia · 2024-11-23

本研究探讨富马酸二甲酯(DMF)与体外光分离置换疗法(ECP)联合治疗皮肤T细胞淋巴瘤(CTCL)的协同作用。体外实验显示两药联用协同诱导CTCL细胞死亡并增强NF-κB抑制,且4例患者接受联合治疗后总缓解率达100%,皮肤和血液至下次治疗时间长达57个月。

要点

  • DMF与ECP联合在CTCL细胞中协同诱导细胞死亡并增强NF-κB抑制。
  • 联合治疗通过降低硫氧还蛋白还原酶活性和谷胱甘肽水平增加ROS产生。
  • 4例患者接受DMF/ECP联合治疗,总缓解率100%,至下次治疗时间长达57个月。

核心结论

  • DMF与ECP联合治疗在体外协同诱导CTCL细胞死亡并增强NF-κB抑制,4例患者总缓解率100%,皮肤和血液至下次治疗时间长达57个月,作者认为该联合方案是高效持久的CTCL疗法。

研究设计与样本

  • 体外实验使用患者来源的SS细胞及CTCL细胞系HH、HuT 78和SeAx,并初步临床转化治疗4例患者。

主要发现

  • DMF与ECP联合在CTCL细胞中协同诱导细胞死亡。
  • 联合治疗较DMF单药进一步增加对CTCL中NF-κB的抑制能力。
  • 联合治疗通过降低硫氧还蛋白还原酶活性和谷胱甘肽水平增加ROS产生,呈现相同协同效应。
  • 细胞死亡抑制剂筛选提示DMF/ECP联合诱导多种细胞死亡机制。
  • 4例患者接受DMF/ECP联合治疗,总缓解率100%,皮肤和血液至下次治疗时间长达57个月。

临床怎么用

  • 作者将DMF与ECP联合治疗引入为高效且持久的CTCL疗法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary cutaneous T cell lymphomas (CTCL) are characterized by high relapse rates to initially highly effective therapies. Combination therapies have proven beneficial, particularly if they incorporate extracorporeal photopheresis (ECP). The NF-κB inhibitor dimethyl fumarate (DMF) has proven a new, effective drug in CTCL in a clinical phase II study. In vitro experiments with patient-derived SS cells and the CTCL cell lines HH, HuT 78, and SeAx revealed a synergistic effect of DMF and ECP on cell death induction in CTCL cells. Furthermore, an additional increase in the capacity to inhibit NF-κB in CTCL was detected for the combination treatment compared to DMF monotherapy. The same synergistic effects could be measured for ROS production via decreased Thioredoxin reductase activity and glutathione levels. Consequently, a cell death inhibitor screen indicated that the DMF/ECP combination treatment induces a variety of cell death mechanisms in CTCL. As a first step into clinical translation, 4 patients were already treated with the DMF/ECP combination therapy with an overall response rate of 100% and a time to next treatment in skin and blood of up to 57 months. Therefore, our study introduces the combination treatment of DMF and ECP as a highly effective and long-lasting CTCL therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Şener ÖÇ, Melchers S, Tengler L, et al. Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma. Leukemia. 2024. PMID: 39580583. doi:10.1038/s41375-024-02479-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。